Abstract
Reports on the prognostic impact of mutations in the RAS proto-oncogenes in patients with acute myeloid leukemia (AML) are conflicting. A peptide nucleic acid (PNA)-based technique was used on 232 AML samples to detect point mutations of the hotspots in N-RAS and K-RAS. No significant correlations between RAS mutations and clinical features, karyotype or FLT3 were found.
Vol. 89 No. 11 (2004): November, 2004 : Letters to the Editor
Published By
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com